Benzinga | Nov 1, 2021 06:43AM EDT

SVB Leerink Maintains Outperform on AbbVie, Lowers Price Target to $135

SVB Leerink analyst Geoffrey Porges maintains AbbVie (NYSE:ABBV) with a Outperform and lowers the price target from $142 to $135.